Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucas Moreno

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 20, 2020
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer NetworkLoredana Amoroso, Victoria Castel, Gianni Bisogno, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2016
Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer studyFernando Carceller, Francisco J Bautista, Irene Jiménez, et al.
Molecular Cancer|September 3, 2022
Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic programCarlos Jiménez, Roberta Antonelli, Mariona Nadal-Ribelles, et al.
Pediatric Blood & Cancer|July 18, 2018
Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN studyDaniel A Morgenstern, Ulrike Pötschger, Lucas Moreno, et al.
Journal of Neuro-Oncology|December 18, 2017
Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of careTeresa de Rojas, Francisco Bautista, Miguel Flores, et al.
Cell Death & Disease|September 18, 2020
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosisLaia París-Coderch, Aroa Soriano, Carlos Jiménez, et al.
Frontiers in Oncology|February 9, 2026
Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisonsHolger N Lode, Przemysław Holko, Aleksandra Wieczorek, et al.
Journal of Medical Genetics|November 29, 2022
Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disordersEstela Carrasco, Adrià López-Fernández, Marta Codina-Sola, et al.
Cancer Research|June 30, 2020
Noninvasive MRI Native T<sub>1</sub> Mapping Detects Response to <i>MYCN</i>-targeted Therapies in the Th-<i>MYCN</i> Model of NeuroblastomaKonstantinos Zormpas-Petridis, Evon Poon, Matthew Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK studyLucas Moreno, Lynley V Marshall, Andrew D J Pearson, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|June 20, 2020
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer NetworkLoredana Amoroso, Victoria Castel, Gianni Bisogno, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2016
Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer studyFernando Carceller, Francisco J Bautista, Irene Jiménez, et al.
Molecular Cancer|September 3, 2022
Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic programCarlos Jiménez, Roberta Antonelli, Mariona Nadal-Ribelles, et al.
Pediatric Blood & Cancer|July 18, 2018
Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN studyDaniel A Morgenstern, Ulrike Pötschger, Lucas Moreno, et al.
Journal of Neuro-Oncology|December 18, 2017
Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of careTeresa de Rojas, Francisco Bautista, Miguel Flores, et al.
Cell Death & Disease|September 18, 2020
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosisLaia París-Coderch, Aroa Soriano, Carlos Jiménez, et al.
Frontiers in Oncology|February 9, 2026
Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisonsHolger N Lode, Przemysław Holko, Aleksandra Wieczorek, et al.
Journal of Medical Genetics|November 29, 2022
Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disordersEstela Carrasco, Adrià López-Fernández, Marta Codina-Sola, et al.
Cancer Research|June 30, 2020
Noninvasive MRI Native T<sub>1</sub> Mapping Detects Response to <i>MYCN</i>-targeted Therapies in the Th-<i>MYCN</i> Model of NeuroblastomaKonstantinos Zormpas-Petridis, Evon Poon, Matthew Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK studyLucas Moreno, Lynley V Marshall, Andrew D J Pearson, et al.
Pageof 13